Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs

Link to full article Enhanced AP-PA02 enters SWARM-P.a. study AP-PA02 identified as lead cocktail for non-cystic fibrosis bronchiectasis Phase 2 trial Distinct phage cocktail (AP-PA03) for pneumonia advances to manufacturing Jan. 5, 2022 The improvements in AP-PA02 reflect Armata’s core strategy of utilizing clinical isolate surveillance data to drive enhancement of product composition. Prior to […]

Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therapeutic Development Programs

Link to full article Nov. 18, 2021 Announces FDA clearance of IND to initiate Phase 1b/2a clinical trial of AP-SA02 in Staphylococcus aureus bacteremia (“diSArm” Study) Achieves significant milestone under previously announced therapeutic development award from the Cystic Fibrosis Foundation for continued advancement of Phase 1b/2a SWARM-P.a. clinical trial of AP-PA02 in Pseudomonas aeruginosa infections […]

Adherium announces the appointment of Lou Panaccio to the Board with Matt McNamara stepping down

Link to Full Article Melbourne, Australia – 25 February 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a provider of integrated digital health solutions and a world leader in connected respiratory medical devices, announces the appointment of Mr Lou Panaccio as a Non-executive director of Adherium with Mr Matthew McNamara stepping down as a […]


An Australian backed and enabled “smart” orthopaedic knee implant set to revolutionise knee replacements has been given marketing authorisation by the US Food and Drug Administration. The canturioTMte device has been backed by Melbourne-based healthcare investment firm, BioScience Managers (BSM) to assist with the aggregation of patient data for software developed by Melbourne-based healthcare informatics […]


Link to full article Cambridge, UK, 11 October 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, continues to build a strong patent portfolio protecting its proprietary Arestat™ technology. Arecor is pleased to announce that its European patent EP2457590 on polysaccharide vaccines has been successfully upheld following opposition […]

WA aged-care provider Hall and Prior to launch ‘world-first’ administration platform

The West Australian Tue, 19 October 2021 3:13PM WA-based Hall and Prior will be the first Australian aged care provider to roll-out a new “world-first” platform designed to reduce human error in the sector. The software developed by Australian company Humanetix automates administration work to free-up time for carers by up to 96 minutes per […]

Humanetix and BioScience Managers partner to launch tech platform globally

Link to full article Humanetix is set for global expansion following a partnership with the international investment firm BioScience Managers (BSM). Humanetix’s main product ACE, is point-of-care documentation, decision-support and clinical workflow IT system that supports staff care delivery for residential aged care residents. The technology has been part of a 2-year trial conducted by the […]

Zimmer Biomet and Canary Medical Announce FDA De Novo Classification Grant and Authorization to Market the World’s First and Only Smart Knee Implant

Link to full article August 30, 2021— Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Canary Medical, a medical data company, today announced U.S. Food and Drug Administration (FDA) DeNovo classification grant and authorization to market the tibial extension for PersonaIQ®, the world’s first and only smart knee cleared […]

CalciMedica Reports Topline Data from the AuxoraTM CARDEA Phase 2 COVID-19 Pneumonia Clinical Trial

Link to full article Reduction in time to recovery through day 60 in patients with moderate and severe respiratory failure (primary endpoint analysis) Statistically significant reduction in time to recovery through day 60 in all patients who received study drug (a pre-specified supplementary analysis of the primary endpoint) Statistically significant 56% relative risk reduction in […]

CalciMedica Announces Publication of Preclinical Data in Journal of Immunology Further Validating Calcium Release-Activated Calcium (CRAC) Channels as Drug Targets for Diseases of the Airways

Link to full article Data provides further evidence of the broad potential for CRAC channel inhibitors to benefit patients across multiple disease areas involving the lungs LA JOLLA, Calif., September 9, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company”), the CRAC channel company, today announced the publication of preclinical data validating calcium release-activated calcium (CRAC) channels, P2Y2 […]